Compare SYNA & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | IDYA |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2001 | 2019 |
| Metric | SYNA | IDYA |
|---|---|---|
| Price | $117.60 | $33.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | ★ $129.33 | $52.29 |
| AVG Volume (30 Days) | ★ 880.2K | 774.5K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $663,588,000.00 | $218,710,000.00 |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $13.85 | $189.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 21.04 | ★ 3024.43 |
| 52 Week Low | $58.28 | $26.81 |
| 52 Week High | $149.11 | $42.68 |
| Indicator | SYNA | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 35.65 |
| Support Level | $115.98 | $29.74 |
| Resistance Level | $121.72 | $35.14 |
| Average True Range (ATR) | 1.73 | 1.29 |
| MACD | 0.18 | -0.38 |
| Stochastic Oscillator | 80.31 | 17.84 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.